Quick Answer
HALOZYME THERAPEUTICS, INC. reported R&D Expense of $79.05 million for fiscal year 2024.
HALOZYME THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $79.05M | +3.5% |
| 2023 | $76.36M | +14.6% |
| 2022 | $66.61M | +86.7% |
| 2021 | $35.67M | +4.2% |
| 2020 | $34.24M | -75.7% |
| 2019 | $140.80M | -6.3% |
| 2018 | $150.25M | -0.3% |
| 2017 | $150.64M | -0.1% |
| 2016 | $150.84M | +61.8% |
| 2015 | $93.24M | +17.0% |
| 2014 | $79.70M | -17.5% |
| 2013 | $96.64M | +38.0% |
| 2012 | $70.04M | +21.7% |
| 2011 | $57.56M | +11.2% |
| 2010 | $51.77M | -8.6% |
| 2009 | $56.61M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.25M | -6.5% | -1.7% |
| June 30, 2025 | $17.54M | -16.6% | +18.5% |
| March 31, 2025 | $14.80M | -22.6% | -19.8% |
| September 30, 2024 | $18.46M | +6.6% | -12.3% |
| June 30, 2024 | $21.04M | +6.6% | +10.1% |
| March 31, 2024 | $19.11M | +6.3% | +10.3% |
| September 30, 2023 | $17.32M | +3.7% | -12.2% |
| June 30, 2023 | $19.73M | +27.4% | +9.7% |
- HALOZYME THERAPEUTICS, INC. showed an increase of +3.5% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2024 period, HALOZYME THERAPEUTICS, INC.’s r&d expense has grown by 39.6% (from $56.61 million to $79.05 million).
- The most recent figure is from HALOZYME THERAPEUTICS, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 18, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: